Medicare AWP Rule: BIO Urges Careful Definition Of “Average Sales Price”
Executive Summary
CMS should follow the House Medicare bill's definition of "average sales price" if it chooses a competitive acquisition model to reform the AWP payment system, the Biotechnology Industry Organization suggests
You may also be interested in...
AWP Reform Reporting Requirements Need Clear Definition, PhRMA Says
The Centers for Medicare & Medicaid Services should clearly define reporting requirements for manufacturers associated with payment reform for Part B drugs, the Pharmaceutical Research & Manufacturers of America said
AWP Reform Reporting Requirements Need Clear Definition, PhRMA Says
The Centers for Medicare & Medicaid Services should clearly define reporting requirements for manufacturers associated with payment reform for Part B drugs, the Pharmaceutical Research & Manufacturers of America said
AWP Reform Must Wait For Congressional Study, Oncologists Say
CMS cannot implement reforms to the AWP-based reimbursement system for Medicare Part B drugs before the General Accounting Office has completed a study requested by Congress, the American Society of Clinical Oncology says